A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for ...

It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...

Custer added that Lilly still expects to file for regulatory approvals of the pill before the end of 2025. The study of overweight or obese adults with weight-related health issues, but not ...